Timothy Romberger - Jun 22, 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role
Director
Signature
/s/ Andrew Gengos, Attorney-in-Fact
Stock symbol
CYT
Transactions as of
Jun 22, 2021
Transactions value $
$0
Form type
4
Date filed
6/24/2021, 08:52 PM
Previous filing
Jun 17, 2021
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Conversion of derivative security +79.1K +27.23% 369K Jun 22, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Series A Convertible Preferred Stock Conversion of derivative security -69.5K -100% 0 Jun 22, 2021 Common Stock 20.4K Direct F1
transaction CYT Series B Convertible Preferred Stock Conversion of derivative security -200K -100% 0 Jun 22, 2021 Common Stock 58.7K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.